EUCTR2014-002702-21-DE进行中（未招募）1 期
A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients - BLAST
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 194
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects must be at least 18 years old at the time of registration
- •2.Histologically or morphologically confirmed diagnosis of AML except for AML M3 (acute promyelocytic leukemia).
- •3.Subjects with AML who achieved complete remission (CR), including CRi and CRp after a maximum number of two cycles of induction chemotherapy (must contain at the minimum cytarabine as well as an anthracycline or mitoxantrone). CR (or CRi or CRp) needs to be confirmed by bone marrow aspirate up to 7 days prior to randomization.
- •4.AML subjects younger than 60 yearswith intermediate or high-risk cytogenetics at the time of diagnosis
- •5.60 years old AML subjects and older at the time of diagnosis can be enrolled into the trial independent of cytogenetics or molecular genetic risk group.
- •6.Subjects must provide written informed consent at screening, prior to performance any study-specific procedures or assessments which are not routinely performed for diagnosis or monitoring of AML, and the subjects must be willing to comply with treatment and to follow up assessments and procedures
- •7.Subjects must have Eastern Cooperative Oncology Group (ECOG) performance status of =2 at screening
- •8.The clinical laboratory values should be as follows (at screening):
- •- WBC < 30.000/µl and > 1000/µl;
- •- Platelets count > 70.000/µl
- •- Creatinine < 1.0 mg/dl. If creatinine is between 1.0mg/dl and 1.3mg/dl, the creatinine clearance should be > 30ml/min as calculated using the Cockroft-Gault formula (See appendix 17.4)
- •9. Women of child-bearing potential must practice an acceptable method of birth control until 6 month after the last dose of treatment was administered [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive or double-barriermethod (condom or diaphragm with spermicide)].
- •Female subjects who are lactating must discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.
- •A male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide) or abstinence during the study.
- •10.Subject is able and willing to comply with the requirements of the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 94
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Relapsed or refractory AML
- •2.Start of induction cycle > 90 days before randomization.
- •3.Subjects who have received >2 cycles of induction chemotherapy for AML therapy.
- •4.Subjects younger than 60 years with favorable cytogenetics (t(8;21) or inv(16) or t(16;16) or t(15;17)) or the confirmed presence of the resulting fusion protein AML1-ETO, CBFB-MYH11 or PML-RARA at the time of diagnosis .
- •5.Subjects for which allogeneic HSCT is planned in CR1. If subject refuses HSCT, participation is allowed.
- •6.Subjects planned for a further maintenance therapy after the end of the protocol defined consolidation therapy.
- •7.Known allergic or hypersensitivity to BL-8040- or Cytarabine or to any of the test compounds, materials
- •8.Use of investigational device or agents within 2 weeks or less than 5 half lifes for each investigational product /device at the time of enrollment. Subjects be treated with an experimental drug for two weeks before randomization. Subjects cannot take part in other clinical trials starting from screening. Registry studies / observational studies are permissible.
- •9.Abnormal liver function tests:
- •- Serum AST/ GOT or ALT/ GPT > 3x upper limit of normal (ULN)
- •- Serum bilirubin: Total bilirubin > 2.0mg/dl or conjugated bilirubin > 0.8mg/dl
- •10.O2 saturation < 92% (on room air)
- •11.Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to:
- •Subject has been diagnosed or treated for another malignancy within 3 years of enrollment, except in situ malignancy, or low-risk prostate, skin or cervical cancer after curative therapy. History of other cancer that according to the Investigator might confound the assessment of the endpoints of the study.
- •A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications.
- •History of any or more of the following cardiovascular conditions: cardiac angioplasty (within 6 months) or stenting (within 6 months) and/or myocardial infarction (MI) (within 6 months) or cerebro-vascular event within the past 6 months, unstable angina, vascular disease, class III or IV, congestive heart failure (as defined by the New York Heart Association (NYHA))•Known central nervous system disease that may jeopardize the subject’s study participation according to the investigator judgement
- •Active, uncontrolled infection.
- •The participation of subject´s receiving long acting insulin (with high protein binding) and oral antidiabetic agents should be weighed by the investigator due to increased susceptibility of hypoglycaemia. If such patients are enrolled, an increased frequency of blood glucose monitoring is required.
- •12.Prior clinically significant grade 3-4 non-hematological toxicity to high-dose cytarabine or grade = 2 of neurological toxicity
- •13.Positive serology for HIV, active Hepatitis C and Hepatitis B (HBsAG pos.).Serology must be performed within 2 months before Randomization..
- •14.Left ventricular ejection fraction (LVEF) of <40% by echocardiogram (ECHO) at screening.
- •15.Subjects with psychological, psychiatric, neurological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
研究者
相似试验
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleEUCTR2006-003067-31-LTETI Pharma GmbH230
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.Moderate to severe atopic eczema with or without rhinitis and/or rhinoconjunctivitis caused by clinical relevant IgE-mediated sensitization against House dust mites (HDM) leading to aggravation of patient’s skin lesions.MedDRA version: 8.1Level: LLTClassification code 10003641Term: Atopic eczemaEUCTR2006-003066-34-DEETI Pharma GmbH
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleRhinitis and/or rhinoconjunctivitis with or without allergic asthma caused by clinical relevant sensitization against tree pollen.MedDRA version: 8.1Level: LLTClassification code 10039083Term: RhinitisEUCTR2006-003067-31-DEETI Pharma GmbH230
进行中（未招募）
1 期
A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patientsSeasonal prophylaxis of influenza in immonucompromised subjectsMedDRA version: 8.1 Level: LLT Classification code 10022000 Term: InfluenzaEUCTR2006-002473-47-GBF.Hoffmann-La Roche Ltd.475
进行中（未招募）
不适用
A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patientsSeasonal prophylaxis of influenza in immonucompromised subjectsMedDRA version: 8.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2006-002473-47-EEF.Hoffmann-La Roche Ltd.470